Deal to delay generic Nexium didn’t violate antitrust laws, jury rules

Lawyers say the suit against AstraZeneca and Ranbaxy has yielded the first jury decision in a so-called pay-for-delay case since a U.S. Supreme Court decision made it easier to challenge such agreements under federal antitrust law.
Modern Healthcare Breaking News

Pharmaceutical Stocks

[stock-ticker]

© 2017 Drugs News All rights reserved.       Privacy Policy       Contact Us